BioSpace News Archive

Relay Therapeutics, Inc. is scheduled to participate in two fireside chats this month at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on Monday, November 14, 2022 at 10:00 a.m. ET and the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, at 1:15 p.m. ET.

ADC Therapeutics SA announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a Phase 2 clinical study of IONIS-FB-L Rx in patients with immunoglobulin A nephropathy (IgAN).

Charles River Laboratories International, Inc. announced the expansion of its cell therapy contract development and manufacturing facility in Memphis, Tenn.

Bicara Therapeutics will present data at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, being held in Boston, Massachusetts from November 8-12, 2022.

Incyte (Nasdaq:INCY) today announced that abstracts featuring data from its oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston and virtually.

Biora Therapeutics, Inc. announced that it has entered into a definitive agreement with institutional investors for the purchase and sale, in a registered direct offering, of 32,506,250 shares of the Company’s common stock and warrants to purchase up to 32,506,250 shares of common stock at a combined offering price of $0.30 per share of common stock and accompanying warrant.

Rallybio Corporation, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, reported financial results for the third quarter ended September 30, 2022 and provided an update on recent program and corporate developments.

Sesen Bio (Nasdaq: SESN ) today reported operating results for the third quarter ended September 30, 2022, and provided a business update.

Gamida Cell Ltd. (Nasdaq: GMDA) today announced encouraging preclinical data on GDA-501, a genetically modified NAM (nicotinamide) Natural Killer (NK) pre-clinical cell therapy candidate from Gamida Cell’s expanding pipeline of cell therapy candidates.